speakers
DESCRIPTION
Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes. This activity was developed by the American Pharmacists Association and the Agency for Healthcare Research and Quality. Speaker Two Rehan Qayyum, M.D. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/1.jpg)
Comparative Effectiveness, Safety, and Indications of Insulin Analogues in
Premixed Formulations for Adults with Type 2 Diabetes
This activity was developed by the American Pharmacists Association and the Agency for Healthcare Research and Quality.
![Page 2: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/2.jpg)
SpeakersSpeakers
Speaker TwoRehan Qayyum, M.D.Assistant Professor of Medicine The Johns Hopkins University School of Medicine Investigator Evidence-based Practice CenterThe Johns Hopkins UniversityBaltimore, MD
Speaker ThreeCarmen Kelly, Pharm.D, R.Ph. Pharmacist OfficerAgency for Healthcare Research
and QualityEffective Health Care
ModeratorBarbara A. Bartman, M.D.,
M.P.H. Medical Officer Agency for Healthcare
Research and QualityEffective Health Care
Speaker OneScott Smith, R.Ph., M.S.P.H.,
Ph.D. Director of Pharmaceutical
Outcomes Research Agency for Healthcare
Research and QualityEffective Health Care
![Page 3: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/3.jpg)
AccreditationAccreditation
APhA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to the
activity by the accredited provider is: 202-999-09-111-H01-P. This activity is approved for 1 contact hour of continuing pharmacy education credit (0.1 CEU).
To obtain continuing pharmacy education credit for this activity, participants must participate in the entire activity, and complete the online posttest and evaluation form located on www.pharmacist.com/education/. A Statement of Credit will be automatically generated upon achieving these requirements. There is no fee to participate in this activity.
ACPE Activity Type: Knowledge-Based Initial Release Date: February 26, 2009
![Page 4: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/4.jpg)
DisclosuresDisclosures
Barbara A. Bartman, M.D., M.P.H., Scott Smith, R.Ph., M.S.P.H., Ph.D., and Carmen Kelly, Pharm.D, R.Ph. have no financial interests or relationships to disclose.
Rehan Qayyum, M.D. received grant support from the Agency for Healthcare Research and Quality (AHRQ) through contract #290-02-0018.
AHRQ’s Office of Communications and Knowledge Transfer staff, The Lewin Group project staff, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.
![Page 5: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/5.jpg)
Learning ObjectivesLearning Objectives
To discuss the effectiveness of premixed insulin analogues in achieving optimal glycemic control, as compared to insulin regimens
To compare the differences in premixed insulin analogues from other commonly used insulin preparations with regard to safety, adverse effects, or adherence
To evaluate the effectiveness and safety of the new premixed insulin analogue regimens in individuals on oral anti-diabetic agents and individuals with different blood glucose patterns or types of control
To discuss practical and effective therapy options for patients with diabetes
![Page 6: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/6.jpg)
Polling Question One
How would you describe your familiarity with AHRQ's Comparative Effectiveness reports?
a. Very Knowledgeable
b. Somewhat Knowledgeable
c. Fairly Unfamiliar
![Page 7: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/7.jpg)
The Effective Health Care Program
Scott Smith, R.Ph., M.S.P.H., Ph.D. Agency for Healthcare Research and Quality
Effective Health Care
![Page 8: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/8.jpg)
Effective Health Care Program Effective Health Care Program 2003 – Present
Authorized in 2003 by Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act
Conducts objective comparisons of the effectiveness of different health care interventions
Goal: To support informed health care decisions by patients, clinicians, and policymakers and improve the quality, effectiveness, and efficiency of health care to support evidence-based practice
![Page 9: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/9.jpg)
Effective Health Care Effective Health Care ProgramProgram
![Page 10: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/10.jpg)
Approaches to Research
Synthesizes existing scientific evidence
Generates new scientific evidence to address gaps
Translates research into plain-language guides
![Page 11: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/11.jpg)
Available Products
![Page 12: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/12.jpg)
How Products Are UsedHow Products Are Used
Inform clinical guideline development
Identify future research priorities
Inform policy, including coverage decisions
Inform clinician and patient decisions
![Page 13: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/13.jpg)
How to Obtain Reports
www.effectivehealthcare.ahrq.gov Full reports and Summary Guides Audio files Spanish translations
AHRQ Publications: (800) 358-9295 Requests for free printed Summary Guides
![Page 14: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/14.jpg)
How to Stay Informed
EHC Web site
E-mail notices
![Page 15: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/15.jpg)
Contacts
AHRQ Effective Health Care E-mail:
Speaker Contact:
Scott R. Smith, R.Ph., [email protected]
![Page 16: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/16.jpg)
Polling Question Two
Are you currently using, or planning to use, AHRQ's Comparative Effectiveness products in your setting?
a. Yes, currently
b. Yes, in the next 12 months
c. Yes, in the next 12 months or later
d. No
![Page 17: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/17.jpg)
Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes
Rehan Qayyum, M.D.Johns Hopkins School of Medicine
Evidence-based Practice Center
![Page 18: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/18.jpg)
Scope of Problem
Diabetes – 7th leading cause of death as listed on death certificates; likely to be under-
reported
Patients with diabetes have twice the risk for death than those without diabetes
Annual direct medical costs = $116 billion 2.3 times higher expenditures in patients with
diabetes than would be in its absence
National diabetes fact sheet 2007. CDC, Atlanta, GA. 2008
![Page 19: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/19.jpg)
Optimal control of hyperglycemia prevents or delays diabetic complications
10% decrease in mortality and 25% decrease in microvascular complications with intensive vs. conventional glucose control in patients with type 2 diabetes (UKPDS)
Suboptimal glucose control with oral hypoglycemic agents insulin
22% of type 2 diabetes patients take insulin
UKPDS. Lancet. 1998;352:837-853.National diabetes fact sheet 2007. CDC, Atlanta, GA. 2008
Glucose Control in Type 2 Diabetes
![Page 20: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/20.jpg)
In adults with type 2 diabetes, what is the effectiveness of premixed insulin analogues in achieving optimal glycemic control as compared to insulin regimens including the following preparations? Premixed human insulin preparations Long-acting insulin analogues administered alone Intermediate-acting human insulin administered alone Short-acting (regular) human insulin administered prandially Rapid-acting insulin analogues administered separately
(prandially) with a long-acting insulin analogue
Key Questions - 1
![Page 21: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/21.jpg)
For adults with type 2 diabetes, do premixed insulin analogues differ from other commonly used insulin preparations with regard to safety, adverse effects, or adherence? The adverse effects of interest include, but
are not limited to, hypoglycemia (nocturnal and daytime), weight gain, and interactions with other medications.
Key Questions - 2
![Page 22: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/22.jpg)
Does the effectiveness or safety of the new premixed insulin analogue regimens vary across the following subpopulations of patients with type 2 diabetes? The elderly (≥ 65 yrs), very elderly (≥ 85 yrs) Other demographic groups (ethnic or racial groups) Individuals with comorbid medical conditions Individuals with limited life expectancy Individuals with disabilities
Key Questions - 3
![Page 23: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/23.jpg)
What are the effectiveness and safety of the new premixed insulin analogue regimens in individuals on oral anti-diabetic agents and individuals with different blood glucose patterns (such as fasting hyperglycemia or postprandial hyperglycemia) or types of control (such as tight control, usual control, good fasting or postprandial control)?
Key Questions - 4
![Page 24: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/24.jpg)
Electronic Databases (February 2008) MEDLINE, EMBASE, CENTRAL (The Cochrane Central Register of
Controlled Trials), CINAHL
Hand Search 13 journals specific to the field References of included articles
Web Sites FDA, EMEA, clinicalstudyresults.org, clinicaltrials.gov
Scientific information packets submitted by Eli Lilly, Sanofi-Aventis, Novo Nordisk
Methods – Search Strategy
![Page 25: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/25.jpg)
Included: Controlled clinical trials, crossover trials,
and observational studies published in English-language peer-reviewed journals
Excluded: Editorials, comments, letters, and abstracts
Two reviewers independently selected studies
Methods – Study Section
![Page 26: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/26.jpg)
Methods – Data Synthesis
Intermediate outcomes (fasting and postprandial glucose, A1c)
Random effects model Adverse effects (hypoglycemia, weight change)
Random effects model Clinical outcomes (rare-event data)
Fixed effects model (Mantel-Haenszel) Sensitivity analysis with Peto’s method and Bayesian
random-effects model
![Page 27: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/27.jpg)
Grading scheme of the GRADE Working Group
Focus was on Study design Number of studies Quality of studies Consistency of evidence
Graded as high, moderate, low, or no evidence
Grading of Stretch of Evidence
![Page 28: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/28.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results
![Page 29: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/29.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results – Fasting Glucose
![Page 30: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/30.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results – Postprandial Glucose
![Page 31: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/31.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results – Hemoglobin A1C
![Page 32: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/32.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results - Hypoglycemia
![Page 33: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/33.jpg)
Mean (kg)Mean (kg) 95%CI95%CI
Long-acting analogues vs.Long-acting analogues vs. All premixed All premixed analoguesanalogues -1.97-1.97 -1.22 to -2.73-1.22 to -2.73
Insulin Aspart 70/30Insulin Aspart 70/30 -2.5-2.5 -1.6 to -3.4-1.6 to -3.4
Insulin Lispro 75/25Insulin Lispro 75/25 No dataNo data
Insulin Lispro 50/50Insulin Lispro 50/50 -1.58-1.58 -0.99 to -2.18-0.99 to -2.18
Non-insulin antidiabetic Non-insulin antidiabetic agents vs.agents vs.
All premixed All premixed analoguesanalogues -2.35-2.35 -0.84 to -3.86-0.84 to -3.86
Insulin Aspart 70/30Insulin Aspart 70/30 -2.82-2.82 -0.61 to -5.02-0.61 to -5.02
Insulin Lispro 75/25Insulin Lispro 75/25 -1.88-1.88 -1.35 to -2.41-1.35 to -2.41
Insulin Lispro 50/50Insulin Lispro 50/50 No dataNo data
Premixed human insulin vs.Premixed human insulin vs. All premixed All premixed analoguesanalogues Not enough dataNot enough data
Results – Weight Change
![Page 34: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/34.jpg)
No or scant data for other comparisons
Results – Other Comparisons
![Page 35: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/35.jpg)
Qayyum et al. Ann Intern Med. 2008; 149:549-559.
Results – Clinical Outcomes
![Page 36: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/36.jpg)
Results – Quality of Life
6 studies evaluated this outcome In 4 studies using validated
measurement tools, only one of six quality of life outcomes (psychological distress) showed a statistically significant difference, in favor of premixed insulin analogues over other anti-diabetic agents
![Page 37: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/37.jpg)
Fasting glucose, postprandial glucose, and hypoglycemia 3 studies; no significant difference
Hemoglobin A1c 3 studies; combination better than
premixed analogues alone Weight change and clinical outcomes
2 studies; no significant difference
Results – In Combinations with Oral Agents
![Page 38: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/38.jpg)
No evidence for: Adherence to treatment regimen Effectiveness and safety in subpopulations
of interest Different intensity of glucose control Targeting fasting versus postprandial
glucose control
Results
![Page 39: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/39.jpg)
* Overall evidence is not of sufficient strength
Qayyum et al. Comparative Effectiveness Review No. 14. AHRQ, Rockville MD. 2008
Long acting Premixed Noninsulin anti-diabetic
FBGIA70/30 ↔↔ ↑↑ ↓↓
IL 75/25 ↑↑ ↔↔ ↓↓
IL 50/50 ↑↑ ↔↔
PPBGIA70/30 ↓↓ ↓↓ ↓↓
IL 75/25 ↓↓ ↓↓ ↓↓
IL 50/50 ↓↓ ↓↓
HbA1cIA70/30 ↓↓ ↔↔ ↓↓
IL 75/25 ↓↓ ↔↔ ↔↔
IL 50/50 ↓↓ ↓↓
HypoglycemiaIA70/30 ↑↑ ↔↔ ↑↑
IL 75/25 ↑↑** ↔↔ ↔↔
IL 50/50 ↑↑ ↔↔
Weight Change
IA70/30 ↑↑ ↔↔ ↑↑
IL 75/25 ↔↔ ↑↑
IL 50/50 ↑↑* * ↔↔
Summary
![Page 40: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/40.jpg)
Premixed analogues vs. long-acting analogues Premixed better in lowering A1c and postprandial glucose Less effective in lowering fasting glucose
Premixed analogues vs. premixed human insulin Better in lowering postprandial glucose Similar in lowering A1c and fasting glucose
Risk of hypoglycemia Premixed analogue similar to premixed human insulin Long-acting insulin analogues better than premixed
analogue
Summary (cont’d.)
![Page 41: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/41.jpg)
Scant data on clinical outcomes No effectiveness data Insufficient data on several comparisons of
interest – e.g., basal-bolus regimen Short duration of followup
Scant data on continued clinical efficacy No data on long-term harm
Scant data on quality of life or adherence
Gaps in Evidence
![Page 42: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/42.jpg)
Problem – uncontrolled A1C Premixed analogues = Premixed human insulin Premixed analogues > Long-acting, oral anti-diabetic
Problem - fasting hyperglycemia Premixed human insulin ≥ Premixed analogues Long-acting > Premixed analogues
Problem – postprandial hyperglycemia Premixed analogues > Premixed human insulin, long-acting
Problem – hypoglycemia Premixed human insulin = Premixed analogues Long-acting > Premixed analogues
Conclusion – Individualized Therapy
![Page 43: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/43.jpg)
Rehan Qayyum, M.D. Shari Bolen, M.D., M.P.H. Nisa Maruthur, M.D. Leonard Feldman, M.D. Lisa M. Wilson, Sc.M. Spyridon S. Marinopoulos, M.D., M.B.A. Padmini Ranasinghe, M.D., M.P.H. Muhammad Amer, M.D. Eric B. Bass, M.D., M.P.H.
Premixed Insulin Analogue Premixed Insulin Analogue TeamTeam
![Page 44: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/44.jpg)
Utility and Value of the Systematic Review:The Unique Position of Pharmacists
Carmen Kelly, Pharm.D., R.Ph.Agency for Healthcare Research and Quality
Effective Health Care
![Page 45: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/45.jpg)
Implications for Practice
Ensuring optimal adherence Help patients make informed choices Cost considerations Safety issues
![Page 46: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/46.jpg)
Comparative effectiveness research will further knowledge about which therapies work best for which individuals
More research needed to “fill the gaps” identified in the report
Implications for Research
![Page 47: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/47.jpg)
Capacity to answer patient questions regarding insulin analogues
Capacity to assist physicians and other health care providers in choosing the right insulin therapy, especially insulin analogues
Implications for Education
![Page 48: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/48.jpg)
Questions and Answers
To submit any followup questions, please e-mail us at:
![Page 49: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/49.jpg)
Obtaining CE Credit
Instructions to Obtain CE Credit for this Activity: 1. Go to www.pharmacist.com/education/. 2. Select Online CE Center, and select Quick List.3. Select activity title from list (ACPE Universal
Activity Number: 202-999-09-111-H01-P). 4. Log in. APhA members, enter your user name and
password. Not an APhA member? It is easy to participate! Just click Create one now to open an account. No fee is required to register.
5. Once you have completed the online posttest and evaluation form, your Statement of Credit will be accessible immediately.
![Page 50: Speakers](https://reader036.vdocuments.us/reader036/viewer/2022062518/568144d6550346895db1a32b/html5/thumbnails/50.jpg)